Heavy Ion Therapy: Who Can Receive It? (As of 2026)

Heavy ion therapy is considered for localized, relatively well-defined solid tumors—such as prostate cancer, hepatocellular carcinoma, certain lung cancers, pancreatic cancer, and bone/soft tissue sarcoma—when surgery is difficult or radiation resistance is an issue. It is not applicable to all cancers.

Key Takeaways

• Heavy ion therapy is considered for localized solid tumors that have relatively well-defined tumor margins and are situated near organs that must not be damaged.
• Example cancer types include prostate cancer, hepatocellular carcinoma, certain lung cancers, pancreatic cancer, and bone/soft tissue sarcoma, with stage 1–3 localized disease being the main target.
• Cancers that have already spread to multiple organs, cancers that grow widely along organ walls like gastric or colorectal cancer, and blood cancers such as leukemia or lymphoma are not standard indications.
• It is considered as an alternative when a patient's age or cardiopulmonary function makes surgery difficult to tolerate, or when tumor location makes surgery difficult; recurrence at a site of prior radiation therapy can also be considered if dose records are available.
• Korea began its first domestic heavy ion therapy in 2023.

What Types of Cancer Can Be Considered for Heavy Ion Therapy?

• The basic condition is a solid tumor that stays localized and has relatively well-defined margins. It is mainly considered for tumors near organs that must not be damaged, such as prostate cancer, hepatocellular carcinoma, certain lung cancers, pancreatic cancer, and bone/soft tissue sarcoma.
• Thanks to the Bragg peak property, where carbon ions stop at a set depth and release their energy all at once, normal tissue in front of and behind the tumor can be relatively spared.
• Because carbon ions are heavier than protons, they cause stronger double-strand DNA breaks, so the therapy is also attempted on tumors that responded poorly to conventional X-ray radiation.
• Surgery remains the principle approach, but heavy ion therapy is considered as an alternative when age or cardiopulmonary function makes surgery hard to tolerate, or when tumor location makes surgery difficult.

When Is It Not an Option?

• Metastatic cancer that has already spread to multiple organs, cancers that grow widely along organ walls with organs in constant motion—such as gastric or colorectal cancer—and blood cancers like leukemia or lymphoma are not standard indications for heavy ion therapy.
• By stage, localized stage 1–3 disease is the main target, and for stage 4, systemic therapy is the principal first approach.
• This does not mean heavy ion therapy is superior for all cancers; for cancers that do not match the indication, surgery or standard radiation therapy may be the better choice.
• It can also be considered for recurrence at a site previously treated with radiation therapy, but in this case, records of the prior irradiation site and dose are essential.

How Is It Specifically Applied in Prostate Cancer and Liver Cancer?

• In prostate cancer, it is used to complete treatment for localized disease in around 12 sessions, and whether it can be applied depends on prior radiation history, presence of an artificial hip joint, and bowel/bladder condition.
• In liver cancer, it is considered for tumors that are unresectable and confined to the liver—particularly those close to major blood vessels or bile ducts where surgery and ablation carry risk. Liver cancer is among the cancers with relatively broad indications for particle therapy, but applicability still depends on liver function and tumor location.
• For prostate cancer, treatment decisions are based on a risk group combining PSA, Gleason score (grade group), and stage, so these three pieces of data are important evidence for assessing eligibility for heavy ion therapy. These detailed criteria can vary by cancer type and individual condition, so this is reference information only.

What Is the Process Before Receiving Treatment?

• Step 1: Prepare recent diagnostic records including CT, MRI, PET-CT (if available), biopsy results, and pathology reports.
• Step 2: If you have previously received radiation therapy, also gather records of the irradiated site, total dose, number of fractions, and dates. This is the single most important record for determining whether re-irradiation is possible.
• Step 3: Add records of surgical and chemotherapy history, written opinions, recent blood tests, kidney/liver function, and current medications so the medical team can assess eligibility.
• Step 4: If deemed eligible, the process moves on to simulation imaging, fabrication of immobilization devices, and treatment planning (1–2 weeks).
• Step 5: Depending on cancer type, patients receive 4–16 sessions, attending 4–5 times per week as outpatients; a total stay of 3–4 weeks, combining planning and treatment, is typical.

FAQ — How Does It Differ From Proton Therapy, and Which One Is Right for Me?

Both are particle radiation therapies, but they have different priorities. Proton therapy is considered when protecting normal tissue is the top priority—for example, in children or tumors near the eyes, brain, or spinal cord—while heavy ion therapy, which uses the strong DNA-damaging effect of carbon ions, is considered for tumors that respond poorly to radiation. Which option is appropriate is determined by the medical team based on stage and tumor location.

FAQ — Is It Still Possible If I've Already Received Radiation Therapy in Another Country?

It depends on the previously irradiated site and total dose. Records of prior radiation therapy (irradiated site, total dose, number of fractions, dates) are key evidence for determining whether re-irradiation is possible. Without these records, making this determination can become difficult.

Sources and Notes

• This article was written based on notes on heavy ion therapy, proton therapy, prostate cancer, and liver cancer (National Cancer Center Korea, NCCN patient guidelines, National Cancer Registry Statistics 2019–2023).
• This content is provided for general medical information purposes only, and diagnosis, treatment methods, and outcomes may vary depending on individual condition. Accurate diagnosis and treatment must be determined through consultation with a medical professional.